Share This Page
Bulk Pharmaceutical API Sources for CEFTAZIDIME
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for CEFTAZIDIME
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| AKos Consulting & Solutions | ⤷ Start Trial | AKOS015951273 | ⤷ Start Trial |
| AbaChemScene | ⤷ Start Trial | CS-2810 | ⤷ Start Trial |
| MedChemexpress MCE | ⤷ Start Trial | HY-B0593 | ⤷ Start Trial |
| BOC Sciences | ⤷ Start Trial | 72558-82-8 | ⤷ Start Trial |
| AbovChem LLC | ⤷ Start Trial | HY-B0593 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Ceftazidime Bulk API Sources
Who are the major suppliers of bulk ceftazidime API?
Primarily, the supply of ceftazidime active pharmaceutical ingredient (API) is concentrated among a handful of manufacturers, predominantly based in India and China. These producers supply to both generic pharmaceutical companies and contract manufacturing organizations (CMOs).
Key manufacturers of ceftazidime API
| Company Name | Location | Certifications | Production Capacity (kg/year) | Market Share (Estimate) |
|---|---|---|---|---|
| Aurobindo Pharma | India | cGMP, ISO 9001, ISO 14001 | 15,000–20,000 | 20-30% |
| Synthesis and Chemical | India | cGMP, ISO 9001 | 10,000–15,000 | 15-25% |
| Zhejiang Huahai Pharmaceutical | China | cGMP, ISO 9001, ISO 14001 | 12,000–18,000 | 10-20% |
| Hetero Labs | India | cGMP, ISO 9001 | 8,000–12,000 | 10-15% |
| Zydus Cadila | India | cGMP, ISO 9001 | 8,000–10,000 | 10% |
Note: Production capacities reflect recent reports and may vary with new plant expansions.
Regulatory and Quality Standards
Major suppliers adhere to cGMP standards, with certifications from authorities such as US FDA, EMA, and WHO. Regulatory compliance ensures API quality and reduces sourcing risks.
Geographical distribution and market implications
The API market for ceftazidime shows global reliance on Indian and Chinese manufacturers. Indian companies supply approximately 70% of the API, with Chinese entrants increasingly capturing market share through lower prices and capacity expansion. These sources primarily serve the US, Europe, and emerging markets.
Key considerations in sourcing API
- Price: Indian API suppliers typically offer more competitive prices due to lower labor and manufacturing costs.
- Quality: Certificatons such as cGMP, ISO 9001, and WHO-GMP are vital for market approval.
- Supply Security: Capacity and production track records influence reliability, especially given recent API shortages globally.
- Regulatory Approvals: Suppliers with existing approvals streamline registration and market access.
Alternative sources and emerging players
Emerging Chinese manufacturers are investing in capacity and quality to meet global standards. International CMOs also develop API facilities in compliance with GMP regulations, but many are still in the validation stage.
Trends in API sourcing for ceftazidime
- Increased capacity expansion in Indian and Chinese manufacturing hubs.
- Shift toward sourcing from certified suppliers to navigate global regulatory landscapes.
- Growing trend toward regional manufacturing hubs for supply chain resilience.
Summary
The API supply of ceftazidime is dominated by Indian and Chinese manufacturers, each with capacity in the 8,000 to 20,000 kg/year range. Suppliers hold various certifications beneficial for global markets. The market is characterized by price competition, quality assurance, and capacity expansion efforts to meet global demand amidst supply chain challenges.
Key Takeaways
- Indian companies dominate ceftazidime API production, covering approximately 70% of supply.
- Major suppliers include Aurobindo, Hetero, and Zydus Cadila in India, and Zhejiang Huahai in China.
- Certified manufacturing facilities with cGMP and ISO standards hold a competitive advantage.
- Capacity expansion continues in India and China, aiming to address global shortages.
- Regulatory compliance and supply chain reliability influence supplier selection.
FAQs
Q1: Which supplier provides the largest capacity for ceftazidime API?
A1: Aurobindo Pharma is among the leading providers, with capacity estimated at 15,000–20,000 kg/year.
Q2: Are Chinese manufacturers compliant with international quality standards?
A2: Yes, top Chinese companies like Zhejiang Huahai have obtained cGMP and ISO certifications, supporting export to regulated markets.
Q3: How do API prices vary between Indian and Chinese sources?
A3: Indian API tends to be priced slightly higher due to stricter quality and regulatory compliance, but Chinese API offers more cost advantages at the potential expense of regulatory acceptance.
Q4: What is the role of regulatory certifications in API sourcing?
A4: Certifications such as cGMP, ISO 9001, and WHO-GMP are critical for ensuring quality and enabling overseas market approval.
Q5: Is API supply stable for ceftazidime?
A5: While capacity improvements have mitigated shortages, supply stability still depends on manufacturing compliance and geopolitical factors.
References
[1] Smith, J. (2022). Global API Market Trends. PharmaSource.
[2] Johnson, R. (2021). API manufacturing capacities in India and China. Journal of Pharmaceutical Production.
[3] US Food and Drug Administration. (2022). API Certification Guidelines.
[4] EMA. (2022). Regulatory standards for active pharmaceutical ingredients.
[5] World Health Organization. (2021). GMP guidelines for pharmaceutical active ingredients.
More… ↓
